Exelixis Inc. logo

Exelixis Inc. (EXEL)

Market Closed
15 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
53. 00
-0.13
-0.2447%
$
13.22B Market Cap
80.72 P/E Ratio
- Div Yield
1.98M Volume
0.61 Eps
$ 53.13
Previous Close
Add Transaction
Day Range
52.03 53.34
Year Range
33.76 53.93
Want to track EXEL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EXEL or ARGX: Which Is the Better Value Stock Right Now?

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 11 months ago
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns

3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns

EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.

Zacks | 11 months ago
3 Reasons Growth Investors Will Love Exelixis (EXEL)

3 Reasons Growth Investors Will Love Exelixis (EXEL)

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Zacks | 11 months ago
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.

Seekingalpha | 11 months ago
Here's Why Exelixis (EXEL) is a Strong Value Stock

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 0 year ago
EXEL or ARGX: Which Is the Better Value Stock Right Now?

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 0 year ago
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 1 year ago
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.

Zacks | 1 year ago
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
Loading...
Load More